Today: 30 April 2026
Browse Category

NASDAQ:CCCS 5 November 2025 - 6 February 2026

CCC Intelligent Solutions stock price whipsaws: premarket bounce follows 13% slide as GM lawsuit surfaces

CCC Intelligent Solutions stock price whipsaws: premarket bounce follows 13% slide as GM lawsuit surfaces

CCC Intelligent Solutions shares rose 1.2% to $5.75 in premarket trading Friday after plunging 12.6% the previous session. Court records show General Motors sued CCC and others in a U.S. design-patent case. CCC also announced expanded access to its estimating software for collision-repair schools following a new workforce study. Quarterly results are due Feb. 24.
6 February 2026
··
The Surprising Upside in CCC Intelligent Solutions (CCCS): Why This Under-the-Radar SaaS Stock Could Soar

The Surprising Upside in CCC Intelligent Solutions (CCCS): Why This Under-the-Radar SaaS Stock Could Soar

CCC Intelligent Solutions reported Q3 2025 revenue of $267.1 million, up 12% year-over-year, with adjusted EBITDA of $110 million, but posted a $2 million net loss due to higher costs. Liberty Mutual signed on to shift much of its casualty claims to CCC’s platform, and the company raised its 2025 revenue guidance. Shares trade near a 52-week low at $8.30, down 35% from the high.
5 November 2025
·

Stock Market Today

  • Avalyn Pharma Raises $300M in Nasdaq IPO to Advance Respiratory Drug Pipeline
    April 30, 2026, 4:14 AM EDT. Avalyn Pharma overshot its target with a $300 million initial public offering (IPO) on Nasdaq under ticker AVLN, exceeding expectations from 11.8 million to 16.6 million shares at $18 each. This funding will support late-stage studies of inhaled versions of approved respiratory drugs, including AP01, an inhaled pirfenidone for idiopathic pulmonary fibrosis, and AP02, an inhaled nintedanib derivative. The company also plans to develop AP03, a combination inhaled therapy. With $138.4 million on hand pre-IPO, Avalyn aims to finance multiple pipeline projects. CEO Lyn Baranowski brings respiratory drug development experience, while the IPO reflects broader biotech trends in reformulating approved medications for improved delivery.

Latest article

Australia Stock Market Today: ASX 200 Falls Again as Oil Shock, Woolworths Warning Hit Shares

Australia Stock Market Today: ASX 200 Falls Again as Oil Shock, Woolworths Warning Hit Shares

30 April 2026
Australian shares fell for an eighth straight session Thursday, with the S&P/ASX 200 closing down 0.24% at 8,665.8 as miners and consumer staples dropped. The decline followed data showing annual inflation rose to 4.6% in March, above the Reserve Bank’s target. Woolworths shares slid up to 9.8% after warning on earnings. Oil prices hit a four-year high, lifting energy stocks 1.4%.
Go toTop